Literature DB >> 30458305

Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers.

Michael J Properzi1, Rachel F Buckley2, Jasmeer P Chhatwal3, Michael C Donohue4, Cristina Lois5, Elizabeth C Mormino6, Keith A Johnson7, Reisa A Sperling3, Aaron P Schultz8.   

Abstract

INTRODUCTION: There is a growing need in clinical research domains for direct comparability between amyloid-beta (Aβ) Positron Emission Tomography (PET) measures obtained via different radiotracers and processing methodologies. Previous efforts to provide a common measurement scale fail to account for non-linearities between measurement scales that can arise from these differences. We introduce a new application of distribution mapping, based on well established statistical orthodoxy, that we call Nonlinear Distribution Mapping (NoDiM). NoDiM uses cumulative distribution functions to derive mappings between Aβ-PET measurements from different tracers and processing streams that align data based on their location in their respective distributions.
METHODS: Utilizing large datasets of Florbetapir (FBP) from the Alzheimer's Disease Neuroimaging Initiative (n = 349 female (%) = 53) and Pittsburgh Compound B (PiB) from the Harvard Aging Brain Study (n = 305 female (%) = 59.3) and the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (n = 184 female (%) = 53.3), we fit explicit mathematical models of a mixture of two normal distributions, with parameter estimates from Gaussian Mixture Models, to each tracer's empirical data. We demonstrate the accuracy of these fits, and then show the ability of NoDiM to transform FBP measurements into PiB-like units.
RESULTS: A mixture of two normal distributions fit both the FBP and PiB empirical data and provides a strong basis for derivation of a transfer function. Transforming Aβ-PET data with NoDiM results in FBP and PiB distributions that are closely aligned throughout their entire range, while a linear transformation does not. Additionally the NoDiM transform better matches true positive and false positive profiles across tracers. DISCUSSION: The NoDiM transformation provides a useful alternative to the linear mapping advocated in the Centiloid project, and provides improved correspondence between measurements from different tracers across the range of observed values. This improved alignment enables disparate measures to be merged on to continuous scale, and better enables the use of uniform thresholds across tracers.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid; Centiloid; Harmonization; Positron emission tomography

Mesh:

Substances:

Year:  2018        PMID: 30458305      PMCID: PMC6338495          DOI: 10.1016/j.neuroimage.2018.11.019

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  36 in total

1.  Different partial volume correction methods lead to different conclusions: An (18)F-FDG-PET study of aging.

Authors:  Douglas N Greve; David H Salat; Spencer L Bowen; David Izquierdo-Garcia; Aaron P Schultz; Ciprian Catana; J Alex Becker; Claus Svarer; Gitte M Knudsen; Reisa A Sperling; Keith A Johnson
Journal:  Neuroimage       Date:  2016-02-23       Impact factor: 6.556

2.  Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods.

Authors:  Susan M Landau; Christopher Breault; Abhinay D Joshi; Michael Pontecorvo; Chester A Mathis; William J Jagust; Mark A Mintun
Journal:  J Nucl Med       Date:  2012-11-19       Impact factor: 10.057

3.  Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.

Authors:  R S Desikan; L K McEvoy; D Holland; W K Thompson; J B Brewer; P S Aisen; O A Andreassen; B T Hyman; R A Sperling; A M Dale
Journal:  AJNR Am J Neuroradiol       Date:  2012-09-13       Impact factor: 3.825

4.  Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia.

Authors:  Christopher C Rowe; Svetlana Pejoska; Rachel S Mulligan; Gareth Jones; J Gordon Chan; Samuel Svensson; Zsolt Cselényi; Colin L Masters; Victor L Villemagne
Journal:  J Nucl Med       Date:  2013-04-10       Impact factor: 10.057

5.  18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

Authors:  Rik Vandenberghe; Koen Van Laere; Adrian Ivanoiu; Eric Salmon; Christine Bastin; Eric Triau; Steen Hasselbalch; Ian Law; Allan Andersen; Alex Korner; Lennart Minthon; Gaëtan Garraux; Natalie Nelissen; Guy Bormans; Chris Buckley; Rikard Owenius; Lennart Thurfjell; Gill Farrar; David J Brooks
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

6.  The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.

Authors:  William E Klunk; Robert A Koeppe; Julie C Price; Tammie L Benzinger; Michael D Devous; William J Jagust; Keith A Johnson; Chester A Mathis; Davneet Minhas; Michael J Pontecorvo; Christopher C Rowe; Daniel M Skovronsky; Mark A Mintun
Journal:  Alzheimers Dement       Date:  2014-10-28       Impact factor: 21.566

7.  Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.

Authors:  Christopher C Rowe; Uwe Ackerman; William Browne; Rachel Mulligan; Kerryn L Pike; Graeme O'Keefe; Henry Tochon-Danguy; Gordon Chan; Salvatore U Berlangieri; Gareth Jones; Kerryn L Dickinson-Rowe; Hank P Kung; Wei Zhang; Mei Ping Kung; Daniel Skovronsky; Thomas Dyrks; Gerhard Holl; Sabine Krause; Matthias Friebe; Lutz Lehman; Stefanie Lindemann; Ludger M Dinkelborg; Colin L Masters; Victor L Villemagne
Journal:  Lancet Neurol       Date:  2008-01-10       Impact factor: 44.182

8.  Functional network integrity presages cognitive decline in preclinical Alzheimer disease.

Authors:  Rachel F Buckley; Aaron P Schultz; Trey Hedden; Kathryn V Papp; Bernard J Hanseeuw; Gad Marshall; Jorge Sepulcre; Emily E Smith; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Jasmeer P Chhatwal
Journal:  Neurology       Date:  2017-06-07       Impact factor: 9.910

9.  18F-Florbetaben PET beta-amyloid binding expressed in Centiloids.

Authors:  Christopher C Rowe; Vincent Doré; Gareth Jones; David Baxendale; Rachel S Mulligan; Santiago Bullich; Andrew W Stephens; Susan De Santi; Colin L Masters; Ludger Dinkelborg; Victor L Villemagne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-22       Impact factor: 9.236

10.  Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies.

Authors:  Yi Su; Shaney Flores; Russ C Hornbeck; Benjamin Speidel; Andrei G Vlassenko; Brian A Gordon; Robert A Koeppe; William E Klunk; Chengjie Xiong; John C Morris; Tammie L S Benzinger
Journal:  Neuroimage Clin       Date:  2018-04-25       Impact factor: 4.881

View more
  6 in total

1.  Association of Emerging β-Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults.

Authors:  Michelle E Farrell; Kathryn V Papp; Rachel F Buckley; Heidi I L Jacobs; Aaron P Schultz; Michael J Properzi; Patrizia Vannini; Bernard J Hanseeuw; Dorene M Rentz; Keith A Johnson; Reisa A Sperling
Journal:  Neurology       Date:  2022-03-25       Impact factor: 11.800

2.  Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease.

Authors:  Huntington Potter; Jonathan H Woodcock; Timothy D Boyd; Christina M Coughlan; John R O'Shaughnessy; Manuel T Borges; Ashesh A Thaker; Balaibail A Raj; Katarzyna Adamszuk; David Scott; Vanesa Adame; Paige Anton; Heidi J Chial; Helen Gray; Joseph Daniels; Michelle E Stocker; Stefan H Sillau
Journal:  Alzheimers Dement (N Y)       Date:  2021-03-24

3.  Exploring common genetic contributors to neuroprotection from amyloid pathology.

Authors:  Mabel Seto; Emily R Mahoney; Logan Dumitrescu; Vijay K Ramanan; Corinne D Engelman; Yuetiva Deming; Marilyn Albert; Sterling C Johnson; Henrik Zetterberg; Kaj Blennow; Prashanthi Vemuri; Angela L Jefferson; Timothy J Hohman
Journal:  Brain Commun       Date:  2022-03-17

4.  Sex differences in the genetic architecture of cognitive resilience to Alzheimer's disease.

Authors:  Jaclyn M Eissman; Logan Dumitrescu; Emily R Mahoney; Alexandra N Smith; Shubhabrata Mukherjee; Michael L Lee; Phoebe Scollard; Seo Eun Choi; William S Bush; Corinne D Engelman; Qiongshi Lu; David W Fardo; Emily H Trittschuh; Jesse Mez; Catherine C Kaczorowski; Hector Hernandez Saucedo; Keith F Widaman; Rachel F Buckley; Michael J Properzi; Elizabeth C Mormino; Hyun Sik Yang; Theresa M Harrison; Trey Hedden; Kwangsik Nho; Shea J Andrews; Douglas Tommet; Niran Hadad; R Elizabeth Sanders; Douglas M Ruderfer; Katherine A Gifford; Xiaoyuan Zhong; Neha S Raghavan; Badri N Vardarajan; Margaret A Pericak-Vance; Lindsay A Farrer; Li San Wang; Carlos Cruchaga; Gerard D Schellenberg; Nancy J Cox; Jonathan L Haines; C Dirk Keene; Andrew J Saykin; Eric B Larson; Reisa A Sperling; Richard Mayeux; Michael L Cuccaro; David A Bennett; Julie A Schneider; Paul K Crane; Angela L Jefferson; Timothy J Hohman
Journal:  Brain       Date:  2022-07-29       Impact factor: 15.255

5.  Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation.

Authors:  Michelle E Farrell; Shu Jiang; Aaron P Schultz; Michael J Properzi; Julie C Price; J Alex Becker; Heidi I L Jacobs; Bernard J Hanseeuw; Dorene M Rentz; Victor L Villemagne; Kathryn V Papp; Elizabeth C Mormino; Rebecca A Betensky; Keith A Johnson; Reisa A Sperling; Rachel F Buckley
Journal:  Neurology       Date:  2020-11-16       Impact factor: 9.910

6.  Genetic variants and functional pathways associated with resilience to Alzheimer's disease.

Authors:  Logan Dumitrescu; Emily R Mahoney; Shubhabrata Mukherjee; Michael L Lee; William S Bush; Corinne D Engelman; Qiongshi Lu; David W Fardo; Emily H Trittschuh; Jesse Mez; Catherine Kaczorowski; Hector Hernandez Saucedo; Keith F Widaman; Rachel Buckley; Michael Properzi; Elizabeth Mormino; Hyun-Sik Yang; Tessa Harrison; Trey Hedden; Kwangsik Nho; Shea J Andrews; Doug Tommet; Niran Hadad; R Elizabeth Sanders; Douglas M Ruderfer; Katherine A Gifford; Annah M Moore; Francis Cambronero; Xiaoyuan Zhong; Neha S Raghavan; Badri Vardarajan; Margaret A Pericak-Vance; Lindsay A Farrer; Li-San Wang; Carlos Cruchaga; Gerard Schellenberg; Nancy J Cox; Jonathan L Haines; C Dirk Keene; Andrew J Saykin; Eric B Larson; Reisa A Sperling; Richard Mayeux; David A Bennett; Julie A Schneider; Paul K Crane; Angela L Jefferson; Timothy J Hohman
Journal:  Brain       Date:  2020-08-01       Impact factor: 13.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.